No, paroxetine exposure through breastfeeding does not cause septal defects in infants.
Septal defects are congenital malformations that develop during the first trimester of pregnancy, not during breastfeeding. The concern about paroxetine and cardiac septal defects relates exclusively to maternal use during early pregnancy (first trimester), when fetal cardiac structures are forming—not to exposure through breast milk after birth 1, 2.
Critical Distinction: Timing of Exposure
First Trimester Pregnancy Exposure (When Septal Defects Form)
- Paroxetine use during the first trimester of pregnancy has been associated with increased risk of cardiac malformations, particularly septal defects 1, 2
- The FDA label specifically warns that epidemiological studies show infants exposed to paroxetine in the first trimester have an increased risk of cardiovascular malformations (1.5-2% vs 1% in general population), primarily ventricular septal defects (VSDs) and atrial septal defects (ASDs) 2
- Meta-analysis data suggest a prevalence odds ratio of 1.5 (95% CI 1.2-1.9) for cardiovascular malformations with first-trimester paroxetine exposure 2
Breastfeeding Exposure (After Birth—Cannot Cause Congenital Defects)
- Paroxetine is present in very low concentrations in breast milk, with infants receiving <3% of the maternal dose 1
- The 2026 OCD guidelines state that "sertraline, fluvoxamine, and paroxetine are present in very low concentrations in the plasma of breast-fed infants (<3% of the maternal dose). It is surmised that they are relatively safe during breastfeeding" 1
- Research demonstrates that paroxetine is detectable in breast milk but at very low levels, and no detectable concentrations were found in nursing infant serum in studied mother-infant pairs 3
Understanding the Biological Impossibility
Congenital heart defects, including septal defects, form during weeks 3-8 of gestation when the fetal heart is developing. By the time an infant is breastfeeding (postpartum period), cardiac development is complete. Exposure to any medication through breast milk cannot retroactively cause structural cardiac malformations that should have formed months earlier during embryogenesis.
Clinical Recommendations for Breastfeeding Mothers
If you are currently breastfeeding and taking paroxetine, you can continue both safely without concern for causing septal defects in your infant:
- Paroxetine is considered relatively safe during breastfeeding due to low infant exposure 1, 4
- Sertraline and paroxetine are considered preferred SSRI agents during lactation 4
- The benefits of treating maternal depression and continuing breastfeeding generally outweigh the minimal risks of low-level medication exposure through breast milk
Important Caveat for Future Pregnancies
If you are planning a future pregnancy or discover you are pregnant while taking paroxetine:
- Paroxetine should ideally be avoided during the first trimester due to the association with cardiac malformations 1
- The 2026 OCD guidelines specifically state: "Paroxetine may be avoided; it may be less safe than the other SSRIs" during pregnancy 1
- Consider switching to an alternative SSRI (such as sertraline) before conception or in early pregnancy after discussion with your physician 1
- Do not abruptly discontinue medication without medical guidance, as untreated maternal psychiatric illness carries its own risks
The absolute risk increase is small even with first-trimester exposure (approximately 0.5-1% increased risk above baseline), and many septal defects resolve spontaneously or are minor 2.